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Background: Although therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel
immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine
modalities that can easily adapt to current and future developments in cancer immunotherapy. One such novel
platform is a DNA vaccine fusing the chemokine Macrophage Inflammatory Protein-3α (MIP-3α) to an antigen, here
melanoma antigen gp100. Previous published work has indicated that MIP-3α targets nascent peptides to immature
dendritic cells, leading to processing by class I and II MHC pathways. This platform has shown enhanced efficacy in
prophylactic melanoma and therapeutic lymphoma model systems.
Methods: The B16F10 melanoma syngeneic mouse model system was utilized, with a standard therapeutic protocol:
challenge with lethal dose of B16F10 cells (5 × 104) on day 0 and then vaccinate by intramuscular electroporation with
50 μg plasmid on days three, 10, and 17. Efficacy was assessed by analysis of tumor burden, tumor growth, and mouse
survival, using the statistical tests ANOVA, mixed effects regression, and log-rank, respectively. Immunogenicity was
assessed by ELISA and flow cytometric methods, including intracellular cytokine staining to assess vaccine-specific
T-cell responses, all tested by ANOVA.
Results: We demonstrate that the addition of MIP3α to gp100 significantly enhances systemic anti-gp100
immunological parameters. Further, chemokine-fusion vaccine therapy significantly reduces tumor burden,
slows tumor growth, and enhances mouse overall survival compared to antigen-only, irrelevant-antigen, and mock
vaccines, with efficacy mediated by both CD4+ and CD8+ effector T cells. Antigen-only, irrelevant-antigen, and
chemokine-fusion vaccines elicit significantly higher and similar CD4+ and CD8+ tumor-infiltrating lymphocyte (TIL)
levels compared to mock vaccine. However, vaccine-specific CD8+ TILs are significantly higher in the
chemokine-fusion vaccine group, indicating that the critical step induced by the fusion vaccine construct is
the enhancement of vaccine-specific T-cell effectors.
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Conclusions: The current study shows that fusion of MIP3α to melanoma antigen gp100 enhances the immunogenicity
and efficacy of a DNA vaccine in a therapeutic B16F10 mouse melanoma model. This study analyzes an adaptable and
easily produced MIP3α-antigen modular vaccine platform that could lend itself to a variety of functionalities, including
combination treatments and neoantigen vaccination in the pursuit of personalized cancer therapy.
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Chemokine-antigen fusion, In vivo electroporationBackground
The recent therapeutic success of immunotherapies [1] and
the identification of cancer neoantigens as potential thera-
peutic targets [2, 3] have generated renewed interest in the
field of cancer vaccines. Although only one therapeutic can-
cer vaccine is currently FDA-approved (Sipuleucel-T [4]),
hypothesized synergies between current and future im-
munotherapies [5] have increased the need for new vaccine
platforms that can best address the new immunotherapeu-
tic opportunities.
DNA vaccines offer many advantages as cancer therap-
ies. They generate effector immunity from all three arms
of the adaptive immune response, particularly including
CD8+ T-cells [6]. They avoid the inclusion of extraneous
and possible deleterious antigens that may be compo-
nents of bacterial or viral-based vaccines [6]. They
stimulate innate immunity and avoid issues of safety and
practicality associated with various vectors [6]. They can
also be readily adapted to novel or mutating antigenic
targets, are stable at room temperature, and can be con-
structed quickly [6]. Clinical trials with a variety of anti-
gens have demonstrated safety and immunogenicity of
clinical DNA vaccines [7, 8]. However, initial trials for
therapeutic DNA cancer vaccines have all shown limited
effectiveness [9]. More recent advances in DNA vaccin-
ation modalities have rekindled interest in their potential
efficacy for cancer therapy [10, 11]. Of note, DNA vac-
cines have shown efficacy in animals, with three licensed
for veterinary use [12–14].
One of the primary hurdles for DNA vaccines has been
their limited potency in the clinical setting [6]. Novel ap-
proaches to in vivo DNA delivery are being developed to ad-
dress this issue. In vivo electroporation has been shown in
animal models to enhance the breadth and potency of elic-
ited immune responses [15–18]. Mechanistic studies have
shown electroporation increases DNA uptake, stimulates
local inflammation at the vaccination site, and enhances
amount of vaccine antigen produced in situ [19–21]. In vivo
electroporation is currently being utilized in the veterinary
clinic as a mode of introducing a hormone into pregnant
sows [22] and is currently undergoing clinical trials [23, 24].
Additionally, investigators have been taking advantage
of the inherent flexibility of DNA to add immunomodu-
lators to the vaccine construct in order to enhance theefficiency of initiating a specific immune response. Many
studies have focused on increasing productive contact of
nascent vaccine antigens to antigen presenting cells
(APCs), especially dendritic cells (DCs). One approach is
to fuse antigens to cytokines such as GM-CSF that can
stimulate the development, proliferation, and maturation
of DCs and monocytes [25–27] or to chemokines like
CCL5 [28], CCL19 [29], MIP3α (also known as CCL20)
[30–35], or other molecules [36–40] that can recruit
and/or target nascent peptides to APCs. MIP3α fusion vac-
cines have been shown to direct antigen to immature DCs
via CCR6 and mediate antigen uptake in a fusion
dependent manner [39], after which, antigens are cross
presented by both MHC class I and II, activating significant
responses from both CD4+ and CD8+ T cells [31–33].
In the current studies, a DNA vaccine administered by
intramuscular electroporation with a construct fusing
MIP3α to the melanoma tumor-associated antigen
gp100 has been analyzed in a therapeutic vaccination
protocol utilizing the B16F10 melanoma mouse model
system. MIP3α-antigen fusion DNA vaccine constructs
have shown efficacy in a prophylactic melanoma model
against gp100 [33], a therapeutic lymphoma model
against oncofetal antigen (OFA) [31], and a prophylactic
malaria model against circumsporozoite protein (CSP)
[30]. Here we compare therapeutic MIP3α-gp100 vaccin-
ation to a construct with a mutated MIP3α sequence
that abrogates its function, effectively providing a gp100
antigen-only vaccine, and to a construct fusing the che-
mokine to an antigen irrelevant to this system, CSP.
These experiments show that inclusion of functional
MIP3α in the vaccine construct used in the therapeutic
protocol enhances immunogenicity, slows tumor growth,
and significantly extends survival compared to antigen-
only and irrelevant-antigen vaccinations.
Methods
Animals and tumor model
Five to six week old female C57BL/6 (H-2b) mice were
purchased from Charles River Laboratories (Wilming-
ton, MA) and maintained in a pathogen-free micro-
isolation facility in accordance with the National Insti-
tutes of Health guidelines for the humane use of labora-
tory animals. All experimental procedures involving
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University (Protocol number MO13H219 and MO16H85).
B16F10 mouse melanoma cells were a generous gift from
Dr. Arya Biragyn (NIH, Baltimore, MD). Six to eight week
old mice were challenged in the left flank subcutaneously
with a lethal dose (5 × 104 cells) of B16F10 melanoma.
Tumor size was recorded as square mm, representing
tumor length × width (opposing axes) measured by cali-
pers every 1–3 days. Mice were kept in the study until one
of the following occurred: mouse death, tumor size eclips-
ing 20 mm in any direction, or extensive tumor necrosis
resulting in excessive bleeding.
Plasmids and vaccination
Vaccine consisted of purified plasmid DNA in endotoxin-
free PBS. The plasmid encoded either MIP3α-gp100,
MIP3α-CSP as described [30], or dMIP3α-gp100 fusion
sequence as described [33]. dMIP3α-gp100 vaccine DNA
is identical except for a point mutation in the chemokine
changing a structurally necessary cysteine to serine (C6S),
which abrogates chemokine functionality [33]. Vaccination
plasmid was extracted from E. coli using Qiagen®
(Germantown, Md) EndoFree® Plasmid Maxi and Giga
Kits. Vaccine DNA purity, quality, and quantity were veri-
fied by gel electrophoresis, restriction enzyme analysis,
Nanodrop® spectrophotometry, and full insert sequencing.
Mock vaccinations comprised of endotoxin-free PBS only.
DNA injections were administered into the hind leg tibi-
alis muscle. Immediately following injection, the muscle
was pulsed using an ECM 830 Electro Square Porator™
with 2-Needle Array™ Electrode (BTX Harvard Appar-
atus®; Holliston, MA) under the following parameters:
106 V; 20 ms pulse length; 200 ms pulse interval; 8 total
pulses. Vaccinations of 50ug/dose were delivered at days
noted in figure legends. Prophylactic efficacy of the vac-
cine was confirmed, replicating previously reported results
in which DNA was delivered by gene gun [33] [Additional
file 1]. Vaccine DNA was also confirmed to express spe-
cific protein after transfection into Hek-293 T cells
[Additional file 2], as detected by Western blot analysis
using antibodies targeting the myc tag present at the 3′
end of the construct. As described by others, vaccination
for the therapeutic model began on day three [41, 42].
In cell ELISA
Humoral immune responses to the vaccine were tested
by an In-Cell ELISA assay to detect overall response to
native B16F10 proteins, including gp100. The studies
utilized the standard protocol for In-Cell ELISA from
Abcam® (Cambridge, UK). In brief, wells of tissue-
culture treated 96-well plates were seeded with 5 × 104
B16F10 cells and were allowed to adhere for 3–4 h at
37 °C. Adherence was verified by microscopy before pro-
ceeding. Cells were fixed, incubated with serum orprimary control antibody (rabbit anti-gp100 ab137078
[Abcam, Inc.; Cambridge, UK]) at varying dilutions
overnight at 4 °C, blocked with 2% BSA, and then in-
cubated with peroxidase-conjugated goat anti-mouse
IgG (serum) or goat anti-rabbit IgG(control) (Jackson
ImmunoResearch Laboratories, West Grove, PA) at a
dilution of 1:5000. Wells were developed for 1 h
using ABTS® ELISA HRP Substrate (KPL, Gaithers-
burg, MD). The data were collected using the Syn-
ergy™ HT (BioTek Instruments, Inc. Winooski, VT).
Extraction of splenocytes and TILs
Spleen and tumor cell suspensions were prepared by
grinding sterile excised tissue between the frosted ends
of microscope slides and then passing the tissue through
a sterile 60 μM mesh. Splenocytes were processed by lys-
ing red blood cells and washing with sterile PBS. Tumor
lysate was washed with sterile PBS, and tumor-
infiltrating lymphocyte (TIL) fraction was enriched by
Lympholyte®-M Cell Separation Media (Cedarlane®,
Burlington, NC) according to the manufacturer’s
protocol. Prior to use all cells were counted by a Z1™
Coulter Counter® (Beckman Coulter, Inc.; Brea, CA)
and/or a hemocytometer with Gibco™ Trypan Blue so-
lution 0.4% (Life Technologies, Carlsbad, CA).
Intracellular cytokine staining and flow cytometry
Enriched splenocytes or TILs were seeded onto Falcon®
Multiwell 24-well tissue culture treated plates (Corning,
Inc.; Corning, NY) at 1 × 106 cells per well (or all cells if
total is less) and stimulated for 3–4 h at 37 °C with
known immunodominant gp10025-33 (KVPRNQDWL)
peptide or control HA (YPYDVPDYA) peptide (JHU
School of Medicine Synthesis & Sequencing Facility;
Baltimore, MD) combined with Protein Transport
Inhibitor Cocktail and costimulatory anti-CD28 and
anti-CD49d agonizing antibodies (eBioscience, Inc.
San Diego, Ca). Cells were collected, washed, fixed,
permeabilized, and stained using standard laboratory
protocols for intracellular staining. Fixation and
permeabilization buffers from Mouse Regulatory T
Cell Staining Kit #2 (eBioscience, Inc. San Diego, Ca)
were used. Stains utilized were the following anti-
mouse mAbs: PercPCy5.5 conjugated anti-CD3, APC-
conjugated anti-IFNγ, FITC-conjugated anti-CD8, and
PE-conjugated anti-CD4 (eBioscience, Inc. San Diego,
CA). Utilized FACSCalibur™ and LSRII™ Flow Cytometers
(BD Biosciences, San Jose, CA). Flow Data analyzed by
FlowJo Software (FlowJo, LLC Ashland, OR).
Lymphocyte depletion
To deplete the CD4+, CD8+, or both T cell subsets, im-
munized mice were injected i.p. with anti-CD4 (GK1.5),
anti-CD8 (2.43), or both mAbs, which were generous
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Negative control vaccinated mice received isotype Rat
IgG2b antibody against KLH (LTF-2) purchased from
BioXCell (West Lebanon, NH). 100 μg of antibody was
given to each mouse i.p. on days -1, 0, and 7 from tumor
challenge. Depletion efficacy was tested on days 0 and 8
or 10 by two-color flow cytometry analysis of peripheral
blood lymphocytes using a FACSCalibur™ cytometer (BD
Biosciences, San Jose, Ca) with FITC conjugated anti-
mouse CD4 and APC-conjugated anti-mouse CD8 mAbs
(eBioscience, Inc. San Diego, Ca).Statistics and availability of data
Tumor size, immunologic, and flow cytometric analyses
were statistically tested by one-way ANOVA with
Bonferonni correction and/or Tukey’s multiple compari-
sons test. Mouse survival studies were statistically tested
by the log-rank test. Tumor time course regressions
were analyzed by mixed effect regression models.
STATA v11.2 (StataCorp, College Station, TX) and Prism
6 (GraphPad Software, Inc. San Diego, CA) were utilized
for statistical analyses and figure creation. Significance
level of α ≤ 0.05 was set for all experiments. The dataset
supporting the conclusions of this article is included
within the article’s additional files [Additional file 3].Results
Systemic immune response
To initially evaluate the immunogenicity of the DNA
construct, systemic immune parameters were examined.
Mice were vaccinated three times at 1 week intervals
and then analyzed 2 weeks after the third immunization.
The MIP3α-gp100 vaccine elicited significantly higher
levels of B16F10-specific antibodies than antigen-only
vaccine, denoted as dMIP3α-gp100 (p = 0.004), and
mock vaccine (p < 0.001; Fig. 1). Interestingly, antigen-
only vaccine had significantly higher B16F10-specific
antibody levels than mock vaccine (p = 0.044).
As was the case for the antibody concentration, the
antigen-only vaccine elicited a moderate vaccine-specific
CD8+ T-cell response that significantly differed from the
mock vaccination by both percentage (p = 0.030; Fig. 1b)
and total number (p < 0.001; Fig. 1c) of CD8+ T cells re-
active to the immunogenic gp10025-33 peptide. The
addition of MIP3α to the vaccine significantly increased
the percentage of (p = 0.049) and total number of (p =
0.026) vaccine induced CD8+ T cells compared to the
antigen only vaccine, increasing the CD8+ T cell num-
bers by 46% (Fig. 1b-c). The MIP3α-gp100 vaccine elic-
ited significantly higher percentages and numbers of
vaccine-specific CD8+ T cells compared to mock vaccin-
ation (p < 0.001 for both; Fig. 1b-c).Therapeutic vaccination model
The potential of this vaccine construct to be utilized in a
therapeutic setting against a solid tumor was assessed,
comparing MIP3α-gp100 vaccination to dMIP3α-gp100,
MIP3α-CSP, and PBS vaccines. A therapeutic regimen
was developed with mice vaccinated on days three, 10,
and 17 post challenge with a lethal dose of B16F10 cells.
Utilizing statistical mixed effects regression models, it
was determined that the overall slope of the tumor
growth regression line was reduced in the MIP3α-gp100
vaccinated group compared to the antigen-only vacci-
nated group by 48% (p = 0.029), to the irrelevant-antigen
group by 56% (p < 0.001), and to the mock vaccine group
by 63% (p < 0.001), whereas mock, antigen-only, and
irrelevant-antigen vaccines showed no significant differ-
ences to each other in slope (Fig. 2a). Slower overall
growth also provides evidence that the differences seen
in these experiments are not due to blocks to tumor
transplantation.
In addition to tumor growth, the tumor burden of
MIP3α-gp100 vaccine recipients proved to be signifi-
cantly lower than mock vaccination at most time-points
tested and significantly lower than antigen only vaccine
on the critical day 14 time-point – the last time point
before any mice were removed from the study. On day
14 post challenge, the average tumor size was reduced in
the MIP3α-gp100 group by 51% compared to the
antigen-only group (p = 0.004), by 54% compared to
irrelevant-antigen group (p = 0.001), and by 55% com-
pared to the mock group (p = 0.001; Fig. 2b). Survival
analysis mirrored tumor growth and burden analyses.
MIP3α-gp100 vaccination significantly enhanced survival
as compared to antigen-only (p = 0.017), irrelevant-
antigen (p = 0.021) and mock (p < 0.001) vaccines.
MIP3α-gp100 vaccination enhanced median survival by
10%, 24% and 24% compared to antigen-only, irrelevant-
antigen, and mock vaccinations, respectively (Fig. 3).
Antigen-only, irrelevant-antigen, and mock vaccinations
did not have significantly different survival curves com-
pared to each other (Fig. 3).
T-cell subset depletion
To determine if effector T-cells played a role in mediat-
ing this enhanced protection, and, if so, which subsets
might be involved, groups of mice were vaccinated three
times over 3 weeks to develop vaccine-specific effector
responses and then were challenged with tumor under
differing depletion conditions: depleting CD4+, CD8+,
both CD4+ and CD8+, and no depletion of T cells.
Figure 4a shows representative flow cytometric analysis
of depletion efficacy. In a mouse lymphoma model, a
similar MIP3α-OFA vaccine showed the CD8+ T-cell ef-
fector response to be essential for protection with the






Fig. 1 Systemic immune parameters of vaccine groups in prophylactic vaccination setting. Mice were vaccinated three times at 1 week intervals
with endotoxin-free PBS, dMIP3α-gp100, and MIP3α-gp100 fusion vaccine. Analysis occurred 2 weeks post third vaccination. Data represent two
independent experiments with 3–5 mice per group per experiment. a Analysis of relative antibody production against B16F10 cells. In-Cell ELISA
performed utilizing fixed B16F10 cells as antigens. Experimental data are shown at a 1:2000 serum dilution after 30-min colorimetric development.
Absorbance values from pre-immune mice were subtracted from post immune mice to obtain the delta absorbance. All groups were significantly
different from each other by ANOVA. b-c Analysis of splenic CD8+ T cells reactive to ex vivo stimulation by gp10025-33 peptide. Activation was
signaled by cytoplasmic IFN-γ accumulation as measured by Intracellular Cytokine Staining Flow Cytometry. Panel b shows the data as percentage
of CD3+ splenocytes. Panel c estimates the total number of reactive CD3 + CD8+ splenocytes by extrapolating flow cytometric data to measured
splenic total cell counts. For both panels, all groups differ significantly from each other, as determined by by ANOVA, *p < 0.05,
**p < 0.01, ***p < 0.001
Gordy et al. Journal for ImmunoTherapy of Cancer  (2016) 4:96 Page 5 of 11However, in this melanoma solid tumor model, depleting
CD4+ or CD8+ T-cells individually show a similar
phenotype as the isotype depletion control. Single deple-
tions have similar tumor growth rates and tumor sizes
compared to isotype depletion (Fig. 4b-c). Importantly,
depleting both subsets of T-cells simultaneously pro-
vided a phenotype similar to the unvaccinated control in
those same analyses (Fig. 4b-c).
Tumor infiltrating lymphocytes
It has been documented that presence and activity of
tumor infiltrating lymphocytes (TILs) can correlate with
anti-tumor responses in melanoma patients [43]. The
intratumoral characteristics of MIP3α-antigen vaccine
responses have not previously been documented. Utiliz-
ing a therapeutic vaccination protocol as outlined, total
CD4+ and CD8+ TILs were harvested 1 week after thesecond vaccination, counted by flow cytometry, and nor-
malized by tumor size. Surprisingly, MIP3α-gp100,
irrelevant-antigen, and antigen-only vaccines all induced
significantly higher CD8+ TIL (all p < 0.001) and CD4+
TIL (all p < 0.01) responses compared to mock vaccine
and were at similar levels to each other (Fig. 5a-b). How-
ever, antigen-only and irrelevant-antigen vaccines did
not provide clinically relevant responses, not differing
significantly from the negative control group in tumor
growth, size, and survival (Figs. 2 and 3). In this system,
TIL levels themselves appear not to correlate with pro-
tection. In addition, vaccine did not significantly alter
levels of tumor-infiltrating CD25 + Foxp3+ regulatory
CD4+ T-cells (Data not shown).
Finally, the levels of CD8+ TILs that secrete IFN-γ
upon stimulation with immunodominant gp10025-33 vac-
cine antigen were assessed. Antigen-only vaccine
a)
b)
Fig. 2 Vaccine effects on tumor growth in therapeutic model.
Vaccinations occurred on days 3, 10, and 17 post challenge. a Tumor
growth rate was assessed between days 10 and 16, day 10 being
the point at which tumor growth of the negative control group
began accelerating and day 16 being the point at which mice
began to be censored due to endpoints being reached. The graph
shows one representative experiment of two, five to seven mice per
group and includes linear regression lines and slopes. The slope of
tumor growth among recipients of MIP3α-gp100 vaccine differed
significantly from dMIP3α-gp100, MIP3α-CSP, and mock PBS vaccination,
as evaluated using a statistical mixed effects regression model. The
groups receiving dMIP3α-gp100 and MIP3α-CSP did not differ
significantly compared to each other or to the group receiving
mock vaccination. Error bars represent standard error. b Tumor
size at day 14 post challenge, the last point before any mice
were removed from experiments. The data are representative of
two experiments, with 5–8 mice per group per experiment. MIP3α-gp100
vaccine recipients had significantly smaller tumors compared to dMIP3α-
gp100, MIP3α-CSP, and mock PBS vaccinated mice, as determined by
ANOVA. dMIP3α-gp100 and MIP3α-CSP were not significantly different
from each other or from mock. *p< 0.05, **p< 0.01, ***p< 0.001
Fig. 3 Vaccine effects on mouse survival in a therapeutic model.
Vaccinations occurred on days 3, 10, and 17 post challenge. Mice
were removed from the study at the following endpoints: death,
tumor size surpassing 2 cm in any dimension, or excessive tumor
bleeding and ulceration. Data representative of two experiments,
5–8 mice per group per experiment. Mice in the MIP3α-gp100
vaccine group exhibit significantly enhanced survival compared to
the dMIP3α-gp100, MIP3α-CSP, and mock PBS vaccination groups by the
log-rank test. dMIP3α-gp100 and MIP3α-CSP did not differ significantly
from each other or from mock. *p< 0.05, **p< 0.01, ***p< 0.001
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gp10025-33-reactive CD8+ TILs by percentage (p < 0.01)
and normalized total numbers (p < 0.05) compared tothe PBS and irrelevant-antigen vaccinated negative control
groups (Fig. 6a-b). MIP3α-gp100 vaccination significantly
enhanced the percentage (p < 0.01) and normalized num-
bers (p < 0.05) of gp10025-33-reactive CD8+ TILs com-
pared to antigen-only vaccine and compared to irrelevant-
antigen (p < 0.001) and mock (p < 0.001). Although the
two vaccines elicit a similar number of total TILs, the
MIP3α-gp100 vaccine elicits a more robust vaccine-
specific effector TIL response that correlates with the en-
hancement of tumor suppression and mouse survival
seen.
Discussion
Our data demonstrate that the addition of the chemo-
kine MIP3α to the gp100 DNA vaccine construct en-
hanced vaccine immunogenicity and therapeutic
potential. Although the antigen-only vaccine elicited a
significant anti-gp100 immune response compared to
the mock vaccine, when utilized as a therapy, only the
MIP3α-gp100 vaccine slowed tumor growth and en-
hanced mouse survival. Further, MIP3α fused to irrele-
vant antigen CSP showed no anti-tumor activity, despite
the previously demonstrated ability of the CSP construct
to function as a highly efficacious vaccine for preventing
malaria in a mouse model system [30]. Previous studies
have conclusively shown that MIP3α must be fused to
its antigen in order to enhance immunogenicity [39].
As has been shown in vitro [32, 33], MIP3α-gp100
vaccine directs the antigen in such a way that both CD4+
and CD8+ effector T-cells can be activated. In this study,
T-cells were depleted after a prophylactic vaccination regi-




Fig. 4 Vaccine effector T-cell responses analyzed by subset depletions. Mice were vaccinated three times at 1 week intervals and then challenged
with a lethal dose (5 × 104) of B16F10 cells. T-cell subsets were depleted one day prior to challenge, on day of challenge, and 7 days post challenge.
Quality of the depletions was assessed by flow cytometric analysis of peripheral blood lymphocytes on days 0 and 8 or 10. a Representative flow
cytometry plots shown depicting CD4 and CD8 expression gated on overall lymphocytes from blood collected at day 10 post challenge. b Tumor
growth regression plot from day 6 to 13 post challenge, assessed by mixed effects regression. c Tumor size at day 13 post challenge, with significance
assessed by ANOVA. All data are from two independent experiments of 4–5 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001
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of the vaccine response. If CD4+ T-cells were depleted in
a therapeutic study, one would not know if the effect was
due to lack of CD4+ anti-tumor effector response or due
to lack of CD4+ T-cell help in the activation of a vaccine-
specific CD8+ T-cell response.
Depletion of either the CD4+ or CD8+ effector T-cell
population showed a protection phenotype similar to the
non-depleted vaccine group, while depletion of both led
to no protection, similar to that observed with mock
vaccination. The lack of protection seen in the double
depletion group provides evidence that antibodies elic-
ited by the vaccine do not provide significant anti-tumor
immunity on their own. Large tumor size outliers in
both single depletion groups suggest that some propor-
tion of the mice are reliant on the depleted subset for
protection, but the overall groups either utilize both ef-
fector subsets relatively equally or one is able to com-
pensate for lack of the other when necessary. The roles
and mechanisms of tumor infiltrating effector CD4+
TILs are complex and still being defined [44], andtherefore the intriguing finding of effector CD4+ T cells
providing therapeutic efficacy in the absence of CD8+ T
cells will be the subject of future work.
Finally, the data show that the therapeutic protection
phenotype provided by MIP3α did not correlate with
overall TILs, but did correlate with gp10025-33 vaccine
peptide-reactive CD8+ TILs, elucidating that the im-
mune activity of and not the quantity of the TILs corre-
lates with therapeutic efficacy.
Vaccine efficacy depends on identification of appropri-
ate target antigens, deliverance of those antigens in a
form that elicits a relevant immune response, adminis-
tration of vaccine by a route that brings it into contact
with the critical immune cells, and selection of effective
adjuvants/immunomodulators. For DNA vaccines,
addition of MIP3α to circumsporozoite protein (CSP)
with vaxfectin adjuvant [30] creates a robust, protective
antibody response against malaria, addition of MIP3α to
oncofetal antigen (OFA) given by gene gun creates a
therapeutic response against lymphoma mediated by
CD8+ T-cells [31], and as reported here, addition of
a)
b)
Fig. 5 Vaccine effects on tumor infiltrating lymphocytes (TILs).
Vaccinations occurred on days 3 and 10 post challenge. Mice were
sacrificed on day 17 and lymphocyte-enriched tumor suspensions
were analyzed by flow cytometry. a shows CD8+ TILs and b CD4+
TILs. Data show one representative experiment with 3–5 mice per
group. Two independent experiments were performed. All three
vaccine formulations have significantly higher CD4 and CD8 TILs
compared to mock vaccination but not to each other, as assessed





Fig. 6 Vaccine-specific CD8+ T-cell tumor infiltrate analysis. Vaccinations
occurred on days 3 and 10 post challenge. Mice were sacrificed on day
17 and lymphocyte-enriched tumor suspensions were collected. CD8+
TILs reactive to ex vivo stimulation by gp10025-33 peptide were
delineated by Intracellular Cytokine Staining Flow Cytometry
measuring cytoplasmic IFN-γ accumulation post stimulation. a
Percentage of CD8+ TILs reactive to antigen. b Estimated total
number of reactive CD8+ TILs normalized to tumor size. All
groups were significantly different from each other by ANOVA
except for the comparison of PBS to MIP3α-CSP. HA irrelevant
negative peptide and PMA/ionomycin positive controls confirmed the
protocol validity (data not shown). Data are from one of two represen-
tative experiments with 3–5 mice per group. *p < 0.05,
**p < 0.01, ***p < 0.001
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creates a therapeutic response against melanoma medi-
ated by both CD4+ and CD8+ effector T-cells. All of
these experiments have shown responses to be signifi-
cantly enhanced by the chemokine in different contexts.
Co-administration of MIP3α can enhance vaccineresponses by enhanced DC recruitment [45]. However,
our previous studies have indicated that in the context
of a DNA fusion vaccine, MIP3α is acting by directing
nascent expressed protein antigens to DCs, not by
recruiting DCs in vivo [30]. Therefore, we hypothesize
that in this context, the pro-inflammatory response elic-
ited by electroporation serves as the adjuvant that
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fused to gp100 then increases the efficiency of nascent
vaccine protein uptake into infiltrating immature den-
dritic cells, resulting in enhanced downstream effector
responses. This research provides further evidence for
the utility of adding chemokine immunomodulators to
vaccine constructs within any immunological context.
A primary strength of this DNA vaccine system is its
modularity and ease of construction. This study shows
that taking the gp100 antigen that induces a specific al-
beit not therapeutically relevant response on its own can
become therapeutically relevant simply by fusing it to
MIP3α. This observation raises the possibility that the
response to more immunogenic antigens could be even
further enhanced by the addition of MIP3α. A burgeon-
ing new field in cancer vaccinology is the utilization of
cancer-specific neoantigens as better vaccine targets that
are not subject to T-cell central tolerance restrictions
[3]. Our modular DNA vaccine could easily and rapidly
be constructed to utilize neoantigens as they are discov-
ered in real time. Testing the principle of this idea will
be the subject of future studies, utilizing now delineated
immunogenic neoantigens found in the B16F10 cell line
[46]. In addition to neoantigens, future studies will also
examine the efficacy of this vaccine system with other
solid tumor models, in combination with current treat-
ments such as immune checkpoint blockade, and in
combination with novel immunomodulators.
Conclusions
In conclusion, our data show that addition of MIP3α en-
hances the immunogenicity and efficacy of a therapeutic
vaccine against the aggressive solid tumor, B16F10
mouse melanoma. The addition of MIP3α to therapeutic
vaccines could present a useful strategy to enhance the
responses of currently studied vaccines. Furthermore,
the modularity of the plasmid provides a realistic plat-
form for creating neoantigen vaccines in a clinically rele-
vant time frame. These findings show that MIP3α can be
a plug and play addition to the cancer immunologist’s
vaccine toolbox that deserves further testing to deter-
mine the true potential of this novel design.
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confirmation. Mice were vaccinated three times over 2 week intervals
with PBS or 50 μg MIP3α-gp100 by i.m. electroporation. Mice were
challenged with a lethal dose of B16F10 (5 × 104) 2 weeks after the third
immunization. Tumor time course was tracked and analyzed by linear
regression models. Tumor growth was found to be significantly reduced
(p < 0.001), replicating prior published data. Data represent one experiment
with 5–6 mice per group. (DOCX 97 kb)
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ladder bands are noted. Full length construct is estimated to be 40 kDa,
consistent with primary band below. (DOCX 169 kb)
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